SCHEMBL498606

SCHEMBL498606

c1csc(C2CCCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 3/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 3/20 0.39
RAB9A P51151 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPC1 O15118 1/20 0.39
HCAR2 Q8TDS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL930295 0.98 MAPT (0.46) MAPTPOLBGAASMN1; SMN2TSHR
SCHEMBL663162 0.98 MAPT (0.46) MAPTPOLBGAASMN1; SMN2TSHR
SCHEMBL7122480 0.95 MAPT (0.44) MAPTPOLBGAASMN1; SMN2TSHR
SCHEMBL8133890 0.95
SCHEMBL28794480 0.91 MAPT (0.42) MAPTPOLBGAASMN1; SMN2TSHR
SCHEMBL497608 0.90
SCHEMBL28657261 0.88 MAPT (0.40) MAPTPOLBGAASMN1; SMN2TSHR
Hydrochloric Acid SCHEMBL11286601 0.87
Acetic Acid SCHEMBL11173187 0.84 BRD4 (0.47) MAPTPOLBGAASMN1; SMN2TSHR
Methylamine SCHEMBL28610020 0.83 MAPT (0.46) MAPTPOLBGAASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4362916-A1 AQUEOUS GEL COMPOSITION Acousia Therapeutics GmbH (DE) 2024-05-08 EP claimed
CN-117881393-A Aqueous gel composition 阿库西亚医疗有限责任公司 2024-04-12 CN claimed
WO-2023222795-A1 AQUEOUS GEL COMPOSITION ACOUSIA THERAPEUTICS GMBH (DE) 2023-11-23 WO claimed
EP-4279061-A1 AQUEOUS GEL COMPOSITION Acousia Therapeutics GmbH (DE) 2023-11-22 EP claimed
US-11548906-B2 Processes for the preparation of SGLT-2 inhibitors, intermediates thereof EMMENNAR PHARMA PRIVATE LIMITED (IN) 2023-01-10 US claimed
CN-110635045-B Water/alcohol soluble organic solar cell anode modification layer material and preparation method thereof 南昌航空大学 2022-08-19 CN claimed
CN-114799615-A Silver powder surface modification method, silver solder paste, and preparation method and application of silver solder paste 深圳先进电子材料国际创新研究院 2022-07-29 CN claimed
CN-113387964-A Cyclopentathiophene organic micromolecule photovoltaic material and preparation method and application thereof 华南理工大学 2021-09-14 CN claimed
US-10913762-B2 Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof MSN LABORATORIES PRIVATE LIMITED (IN) 2021-02-09 US claimed
US-20200331946-A1 PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF EMMENNAR PHARMA PRIVATE LIMITED, (IN) 2020-10-22 US claimed
EP-0560055-B1 Immuno-suppressing enepyranose derivatives ISHIHARA SANGYO KAISHA (JP) 2002-08-28 EP claimed
EP-0465913-B1 Diaminotrifluoromethylpyrimidine derivatives, process for their production and phospholipase A2 inhibitor containing them ISHIHARA SANGYO KAISHA (JP) 1997-09-10 EP claimed
US-5492908-A ANTIARTHRITIC ISHIHARA SANGYO KAISHA LTD. (JP) 1996-02-20 US claimed
US-5348967-A Diaminotrifluoromethylpyridine derivatives, process for their production and phospholipase A2 inhibitor containing them ISHIHARA SANGYO KAISHA LTD. (JP) 1994-09-20 US claimed
US-5304657-A Insecticides ISHIHARA SANGYO KAISHA LTD. (JP) 1994-04-19 US claimed
EP-0483647-A1 Hydrazine compounds or their salts, processes for producing them and pesticides containing them ISHIHARA SANGYO KAISHA, LTD. (JP) 1992-05-06 EP claimed
EP-0465913-A2 Diaminotrifluoromethylpyrimidine derivatives, process for their production and phospholipase A2 inhibitor containing them ISHIHARA SANGYO KAISHA, LTD. (JP) 1992-01-15 EP claimed
US-4235938-A AUGMENTING BACON OR CARMEL FLAVOR INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1980-11-25 US claimed
US-4005138-A REACTION OF DISULFIDES OR MERCAPTANS WITH NITROGEN OXIDES AND HYDROGEN FLUORIDE CIBA-GEIGY CORPORATION (US) 1977-01-25 US claimed
US-3966988-A Flavoring compositions and processes utilizing dithiazine compounds INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1976-06-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548906-B2 Processes for the preparation of SGLT-2 inhibitors, intermediates thereof SLC5A2, SLC5A1, SLC2A4 MAPT 340/4885POLB 4657/4885GAA 147/4885
US-10913762-B2 Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof ALG1, FBP1, DAD1 MAPT 2138/4885POLB 3632/4885GAA 516/4885
US-20200331946-A1 PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF SLC5A2, SLC5A1, SLC2A4 MAPT 340/4885POLB 4657/4885GAA 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.